CN114588062A - Essence for facial care matched with 5D carved fascia therapy - Google Patents
Essence for facial care matched with 5D carved fascia therapy Download PDFInfo
- Publication number
- CN114588062A CN114588062A CN202210247716.6A CN202210247716A CN114588062A CN 114588062 A CN114588062 A CN 114588062A CN 202210247716 A CN202210247716 A CN 202210247716A CN 114588062 A CN114588062 A CN 114588062A
- Authority
- CN
- China
- Prior art keywords
- essence
- carved
- components
- facial care
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003195 fascia Anatomy 0.000 title claims abstract description 28
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 28
- 230000001815 facial effect Effects 0.000 title claims abstract description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 18
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229920001184 polypeptide Polymers 0.000 claims abstract description 16
- 150000001413 amino acids Chemical class 0.000 claims abstract description 10
- 229920006037 cross link polymer Polymers 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims abstract description 9
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 8
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 8
- YDSVPIYLRFZLAT-UHFFFAOYSA-N C(C)(=O)O.C(C)(=O)O.NC(CCC(=O)NCC1=CC=CC=C1)N Chemical compound C(C)(=O)O.C(C)(=O)O.NC(CCC(=O)NCC1=CC=CC=C1)N YDSVPIYLRFZLAT-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 8
- 108010035532 Collagen Proteins 0.000 claims abstract description 8
- 102000008186 Collagen Human genes 0.000 claims abstract description 8
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 8
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 8
- 229920001436 collagen Polymers 0.000 claims abstract description 8
- 238000000855 fermentation Methods 0.000 claims abstract description 8
- 230000004151 fermentation Effects 0.000 claims abstract description 8
- 229940101267 panthenol Drugs 0.000 claims abstract description 8
- 239000011619 pantothenol Substances 0.000 claims abstract description 8
- 235000020957 pantothenol Nutrition 0.000 claims abstract description 8
- 239000004475 Arginine Substances 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 14
- 235000009697 arginine Nutrition 0.000 claims description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 14
- 235000018977 lysine Nutrition 0.000 claims description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 10
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 235000003704 aspartic acid Nutrition 0.000 claims description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 7
- 229960003067 cystine Drugs 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- 235000014304 histidine Nutrition 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 235000004400 serine Nutrition 0.000 claims description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 6
- 239000004386 Erythritol Substances 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 6
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 6
- 235000019414 erythritol Nutrition 0.000 claims description 6
- 229940009714 erythritol Drugs 0.000 claims description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 6
- GKPMARPRXONRJX-BWJWTDLKSA-N (3s)-4-[[(2s,3s)-1-[[(2s)-1-amino-5-(carbamoylamino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-[[(2s)-2,6-diaminohexanoyl]amino]-4-oxobutanoic acid Chemical compound NC(=O)NCCC[C@@H](C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN GKPMARPRXONRJX-BWJWTDLKSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 5
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 claims description 4
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 4
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 4
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 4
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 claims description 4
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 claims description 3
- 108010038807 Oligopeptides Proteins 0.000 claims description 3
- 102000015636 Oligopeptides Human genes 0.000 claims description 3
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Polymers CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 claims description 2
- 229940093441 palmitoyl oligopeptide Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 230000003020 moisturizing effect Effects 0.000 abstract description 14
- 238000001035 drying Methods 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 5
- IHQDGXUYTSZGOG-UHFFFAOYSA-N Erucin Chemical compound CSCCCCN=C=S IHQDGXUYTSZGOG-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- VYZKQGGPNIFCLD-UHFFFAOYSA-N 3,3-dimethylhexane-2,2-diol Chemical compound CCCC(C)(C)C(C)(O)O VYZKQGGPNIFCLD-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 239000001140 aloe barbadensis leaf extract Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- -1 butyryl benzyl amide diacetate Chemical compound 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention provides essence for facial care matched with a 5D carved fascia therapy, which comprises the following components: water, cellulose gum, panthenol, soluble collagen, 1, 2-glycol, a bacillus fermentation product, erucidine, acrylic acid (ester), alkanol acrylate cross-linked polymer, dipeptide diaminobutyryl benzylamide diacetate, p-hydroxyacetophenone, polypeptide and amino acid. The essence for facial care, which is used in cooperation with the 5D carved fascia therapy, contains various polypeptide components and amino acid components, and amino acid components are compounded through the polypeptide components, so that the effects of moisturizing skin, filling and drying the bottom of the skin, improving the lusterless but rough skin and enabling the skin to be watery and transparent can be achieved.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to essence for facial care matched with a 5D carved fascia therapy.
Background
The 5D refined fascia therapy is through bulldozing, the little complete is realized to modes such as massage bare-handed, the fascia reforming, can the cell regeneration repair impaired cell, the moisturizing has compact moisturizing, repair the cell, the effect of anti-attenuation age, need maintain the facial moist compact effect of 5D refined fascia therapy through scribbling the skin care products that the moisturizing is compact behind the 5D refined fascia therapy, but do not have the essence that uses after specially aiming at 5D refined fascia therapy at present, ordinary skin care essence on the market, the composition function is single, the moisturizing compact effect is not good enough, can not satisfy the demand of facial skin nursing behind 5D refined fascia therapy, can only maintain the facial state behind the 5D refined fascia therapy in short time, and can not further promote facial skin state.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides the essence for facial care used in cooperation with a 5D refined fascia therapy, and solves the problems that the existing common skin care essence is single in component function, poor in water replenishing and tightening effects, incapable of meeting the requirements of facial skin care after the 5D refined fascia therapy, only capable of maintaining the facial state after the 5D refined fascia therapy in a short time, and incapable of further improving the facial skin state.
(II) technical scheme
In order to achieve the purpose, the invention is realized by the following technical scheme: the essence for facial care matched with 5D carved fascia therapy is characterized in that: comprises the following components: water, cellulose gum, panthenol, soluble collagen, 1, 2-glycol, a bacillus fermentation product, erucidine, acrylic acid (ester), alkanol acrylate cross-linked polymer, dipeptide diaminobutyryl benzylamide diacetate, p-hydroxyacetophenone, polypeptide and amino acid;
and is divided into major components and minor components.
Preferably, the polypeptide comprises: arginine/lysine polypeptide, acetyl hexapeptide-8, palmitoyl tripeptide-5 and oligopeptide-1.
Preferably, the amino acids include: aspartic acid, arginine, serine, alanine, glutamic acid, histidine, tryptophan, cystine, glycine, lysine and proline.
Preferably, the main components are water, cellulose gum, panthenol, soluble collagen, acetyl hexapeptide-8, 1, 2-glycol, bacillus fermentation product, erucin, acrylic acid (ester), alkanol acrylate cross-linked polymer, oligopeptide-1, palmitoyl tripeptide-5, dipeptide diaminobutyryl benzyl amide diacetate and p-hydroxyacetophenone.
Preferably, the contents of the main components are respectively as follows: 1.3-2.5% of cellulose gum, 2.7-4.8% of panthenol, 1.8-2.7% of soluble collagen, 80.8-1.5% of acetyl hexapeptide, 0.5-2.5% of 1, 2-ethylene glycol, 0.5-1.8% of bacillus fermentation product, 0.3-0.8% of monocalcine, 0.5-0.8% of acrylic acid (ester), 2.3-3.8% of alkanol acrylate cross-linked polymer, 10.9-1.8% of oligopeptide, 50.4-1.1% of palmitoyl tripeptide, 2.2-3.5% of dipeptide diaminobutyrylbenzyl amide diacetate, 0.3-0.5% of p-hydroxyacetophenone and the balance of water.
Preferably, the minor ingredients are: arginine, serine, glutamic acid, tryptophan, proline, glycine, aspartic acid, lysine, alanine, arginine/lysine polypeptide, histidine, cystine.
Preferably, the trace components further comprise sodium hyaluronate, caprylyl hydroximic acid, tripeptide-10 citrulline and erythritol.
Preferably, the trace components comprise 0.9-2.3% of arginine, serine, glutamic acid, tryptophan, erythritol, proline, glycine, aspartic acid, lysine, alanine, arginine/lysine polypeptide, histidine and cystine, and 0.1-0.3% of sodium hyaluronate, caprylyl hydroximic acid, tripeptide-10 citrulline and erythritol.
(III) advantageous effects
The invention provides essence for facial care, which is used in cooperation with a 5D carved fascia therapy. The method has the following beneficial effects:
the essence for facial care, which is used in cooperation with the 5D carved fascia therapy, contains various polypeptide components and amino acid components, and amino acid components are compounded through the polypeptide components, so that the effects of moisturizing skin, filling and drying the bottom of the skin, improving the lusterless but rough skin and enabling the skin to be watery and transparent can be achieved.
Detailed Description
The following will clearly and completely describe the technical solutions in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.
The first embodiment is as follows:
the facial care essence used in combination with 5D carved fascia therapy comprises 1.3% of cellulose gum, 3% of panthenol, 2% of soluble collagen, 81.2% of acetyl hexapeptide, 0.8% of 1, 2-ethylene glycol, 1.2% of bacillus fermentation product, 0.6% of monocalcine, 0.6% of acrylic acid (ester), 2.8% of alkanol acrylate cross-linked polymer, 11.3% of oligopeptide, 51% of palmitoyl tripeptide, 3% of dipeptide diaminobutyryl benzylamide diacetate, 0.3% of p-hydroxyacetophenone, 0.08% of sodium hyaluronate, 0.05% of octanoyl hydroximic acid, 0.04% of tripeptide-10 citrulline and 0.03% of erythritol.
Example two:
in addition to example one, arginine 0.07, serine 0.08, glutamic acid 0.07, tryptophan 0.09, proline 0.09, glycine 0.08, aspartic acid 0.09, lysine 0.09, alanine 0.08, arginine/lysine polypeptide 0.07, histidine 0.09, and cystine 0.06 were added.
Comparative example: the moisturizing and firming essence is popular in the market, and comprises the components of butanediol, jojoba wax PEG-120 esters, trimethylpentanediol/adipic acid/glycerin cross-linked polymer, betaine, algae extract, acryloyl dimethyl ammonium taurate/behenyl polyether-25 methacrylate cross-linked polymer, sodium hyaluronate, sphingolipids and oligopeptide-1; aloe vera leaf juice, the balance water.
The first experimental example: the skin moisture effect test was performed on experimental example 1, experimental example 2 and comparative example by a skin moisture tester, and six subjects were invited to use without any skin care product applied after 5D carved fascia treatment for one day, the product of example one was used for subject 1, the product of example one was used for subject 2, the product of example two was used for subject 3, the product of example two was used for subject 4, the product of comparative example was used for subject 5 and subject 6, and the skin condition of initial use, skin condition of half hour after use, skin condition of three hours after use, and skin condition of six hours after use were tested, and the test results are shown in the following table:
therefore, the moisturizing effect of the product in the second embodiment is the best, the moisturizing effect of the product in the first embodiment is the second best, the moisturizing effect of the product in the third embodiment is relatively weak, and the product cannot play a role in moisturizing the skin for a long time, the moisturizing and tightening effects of the essence are improved by the aid of the peptides, the butyryl benzyl amide diacetate and other components in the first embodiment, the activity of activated cells is further improved by combination of the amino acids and the peptides, the absorption capacity of the skin on the essence is improved, and the water locking effect of the cells is better.
Experiment example two: the test example 6 subjects were again invited to a trial for one month and after one month, skin moisture effect test was performed by a skin moisture tester without wiping any skin care product, and the test results of the test subjects 1 and 2 using the product of example one, the test subjects 3 and 4 using the product of example two, and the test subjects 5 and 6 using the product of comparative example were compared with the initial skin condition of the test example one day after 5D anaglyphic therapy was performed, and the comparison results are shown in the following table:
| initial skin condition | Skin condition after one month | |
| Subject 1 | 48.1％ | 48.2％ |
| Subject 2 | 45.3％ | 44.9％ |
| Subject 3 | 47.0％ | 47.2％ |
| Subject 4 | 43.8％ | 44.0％ |
| Subject 5 | 48.9％ | 46.3％ |
| Subject 6 | 46.1％ | 44.2％ |
Therefore, the product in the second embodiment can maintain the effect of continuously moisturizing and tightening after the 5D carved fascia therapy for a long time and achieve the effect of further improving the skin, the product in the second embodiment, which is not completely added with the components of the invention, can well maintain the moisturizing and tightening effect of the skin, and the product in the comparative example cannot well maintain the skin effect.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (8)
1. The essence for facial care matched with 5D carved fascia therapy is characterized in that: comprises the following components: water, cellulose gum, panthenol, soluble collagen, 1, 2-glycol, a bacillus fermentation product, erucidine, acrylic acid (ester), alkanol acrylate cross-linked polymer, dipeptide diaminobutyryl benzylamide diacetate, p-hydroxyacetophenone, polypeptide and amino acid;
and is divided into major components and minor components.
2. The essence for facial care according to claim 1, for use in combination with 5D carved fascia therapy, wherein: the polypeptide comprises: arginine/lysine polypeptide, acetyl hexapeptide-8, palmitoyl tripeptide-5 and oligopeptide-1.
3. The essence for facial care according to claim 2, wherein the essence is used in combination with 5D carved fascia therapy, and comprises: the amino acids include: aspartic acid, arginine, serine, alanine, glutamic acid, histidine, tryptophan, cystine, glycine, lysine, proline.
4. The essence for facial care according to claim 3, wherein the essence is used in combination with 5D carved fascia therapy, and comprises: the main components are water, cellulose gum, panthenol, soluble collagen, acetyl hexapeptide-8, 1, 2-glycol, bacillus fermentation products, erucidine, acrylic acid (ester), alkanol acrylate cross-linked polymer, oligopeptide-1, palmitoyl tripeptide-5, dipeptide diaminobutyryl benzylamide diacetate and p-hydroxyacetophenone.
5. The essence for facial care according to claim 4, wherein the essence is used in combination with 5D carved fascia therapy, and comprises: the contents of the main components are respectively as follows: 1.3-2.5% of cellulose gum, 2.7-4.8% of panthenol, 1.8-2.7% of soluble collagen, 80.8-1.5% of acetyl hexapeptide, 0.5-2.5% of 1, 2-ethylene glycol, 0.5-1.8% of bacillus fermentation product, 0.3-0.8% of monocalcine, 0.5-0.8% of acrylic acid (ester), 2.3-3.8% of alkanol acrylate cross-linked polymer, 10.9-1.8% of oligopeptide, 50.4-1.1% of palmitoyl tripeptide, 2.2-3.5% of dipeptide diaminobutyrylbenzyl amide diacetate, 0.3-0.5% of p-hydroxyacetophenone and the balance of water.
6. The essence for facial care according to claim 3, wherein the essence is used in combination with 5D carved fascia therapy, and comprises: the micro-components are as follows: arginine, serine, glutamic acid, tryptophan, proline, glycine, aspartic acid, lysine, alanine, arginine/lysine polypeptide, histidine, cystine.
7. The essence for facial care according to claim 6, wherein the essence is used in combination with 5D carved fascia therapy, and comprises: the trace components also comprise sodium hyaluronate, caprylyl hydroximic acid, tripeptide-10 citrulline and erythritol.
8. The essence for facial care according to claim 7, for use in combination with 5D anaglyph fascial therapy, wherein: the trace components comprise 0.9-2.3% of arginine, serine, glutamic acid, tryptophan, proline, glycine, aspartic acid, lysine, alanine, arginine/lysine polypeptide, histidine and cystine, and 0.1-0.3% of sodium hyaluronate, caprylyl hydroximic acid, tripeptide-10 citrulline and erythritol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210247716.6A CN114588062A (en) | 2022-03-14 | 2022-03-14 | Essence for facial care matched with 5D carved fascia therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210247716.6A CN114588062A (en) | 2022-03-14 | 2022-03-14 | Essence for facial care matched with 5D carved fascia therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114588062A true CN114588062A (en) | 2022-06-07 |
Family
ID=81817285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210247716.6A Pending CN114588062A (en) | 2022-03-14 | 2022-03-14 | Essence for facial care matched with 5D carved fascia therapy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114588062A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109464337A (en) * | 2018-12-23 | 2019-03-15 | 广州航美化妆品有限公司 | Compact anti-wrinkle essence |
| CN109984952A (en) * | 2017-12-29 | 2019-07-09 | 广州佳洁化妆品有限公司 | A kind of Essence and preparation method of the compounding removing wrinkle and resisting aging containing a variety of small-molecule peptides |
| CN113693955A (en) * | 2020-10-09 | 2021-11-26 | 广州俏姿颜化妆品有限公司 | Essence liquid |
-
2022
- 2022-03-14 CN CN202210247716.6A patent/CN114588062A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109984952A (en) * | 2017-12-29 | 2019-07-09 | 广州佳洁化妆品有限公司 | A kind of Essence and preparation method of the compounding removing wrinkle and resisting aging containing a variety of small-molecule peptides |
| CN109464337A (en) * | 2018-12-23 | 2019-03-15 | 广州航美化妆品有限公司 | Compact anti-wrinkle essence |
| CN113693955A (en) * | 2020-10-09 | 2021-11-26 | 广州俏姿颜化妆品有限公司 | Essence liquid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106109296B (en) | A kind of moisturizing essence lotion and preparation method thereof | |
| CN109998953A (en) | It is a kind of for improving the polypeptide Essence of skin quality | |
| CN112603849A (en) | Anti-aging composition, essence and preparation method thereof | |
| CN113616566B (en) | Skin care essence for tightening skin and preparation method thereof | |
| CN111419755B (en) | Agilawood fullerene essence and preparation method thereof | |
| CN105616325A (en) | Nacre-based tightening and moisturizing facial mask and manufacturing method thereof | |
| CN111773130A (en) | Hydroxypropyl tetrahydropyrane triol compound and preparation method and application thereof | |
| CN110713517B (en) | Hyaluronan oligopeptide and preparation and application methods thereof | |
| CN112263505A (en) | Copper peptide composition and preparation method and application thereof | |
| CN111110584A (en) | Skin care composition with moisturizing and anti-aging effects and preparation method thereof | |
| CN111329780A (en) | Moisturizing and repairing facial cream capable of tightening wrinkles and preparation method thereof | |
| CN113350230A (en) | Anti-aging composition and preparation method and application thereof | |
| CN114588062A (en) | Essence for facial care matched with 5D carved fascia therapy | |
| CN111568797A (en) | Composition for quickly removing fine lines and application thereof | |
| CN114376940B (en) | Amino acid ice crystal shower gel and preparation method thereof | |
| CN113384497B (en) | Composition and cosmetic for double moisturizing, repairing and improving skin elasticity | |
| CN110090169A (en) | A kind of hyaluronic acid nti-freckle gel | |
| CN103191040A (en) | Night cream and preparation method thereof | |
| CN114983856B (en) | Blue copper peptide solution with penetration promoting system and preparation method and application thereof | |
| CN114306120A (en) | Application of concentrated composite signal peptide in repairing and regenerating skin care product | |
| CN113749967A (en) | Peptide composition and application thereof | |
| CN113116742A (en) | Composite polypeptide anti-wrinkle composition and preparation method and application thereof | |
| CN103919695A (en) | Selenium-containing dressing agent | |
| CN1679502A (en) | Use of DL-cysteine or its salt in cosmetics preparation | |
| Łubkowska et al. | Synthesis of α-collagen fragments and research of their influence on the degree of hydration of a model of epidermis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |